Aachen

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia2 trials
• Coronary artery disease2 trials
• Prostate cancer2 trials
• Stroke2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Familial hypercholesterolaemia1 trial
• Hidradenitis suppurativa1 trial
• Myeloproliferative neoplasms1 trial
• Psoriasis1 trial
• Psoriatic arthritis1 trial
• and 1 more

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 11 trial
• Phase 41 trial

Status

• Active, not recruiting6 trials
• Completed5 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals12 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

  NCT06531499· Phase 1· Novartis Pharmaceuticals· Source

• Recruiting

  Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

  NCT06517719· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

  NCT05921994· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT04747613· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer1 recruiting

Closed trials

• Completed

  Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

  NCT05630001· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

  NCT05362903· Novartis Pharmaceuticals· Source

• Completed

  Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

  NCT04632927· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source